The measurement of ambulatory impairment in multiple sclerosis

被引:85
作者
Schwid, SR
Goodman, AD
Mattson, DH
Mihai, C
Donohoe, KM
Petrie, MD
Scheid, EA
Dudman, JT
McDermott, MP
机构
[1] UNIV ROCHESTER, MED CTR, DEPT NEUROL, ROCHESTER, NY 14642 USA
[2] UNIV ROCHESTER, MED CTR, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA
[3] UNIV ROCHESTER, MED CTR, DEPT BIOSTAT, ROCHESTER, NY 14642 USA
关键词
D O I
10.1212/WNL.49.5.1419
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this study was to examine the relationships between continuous measures of ambulatory impairment in MS patients and their ordinal counterparts. Much of the disability caused by MS is due to ambulatory impairment. The Expanded Disability Severity Scale (EDSS) and the Ambulation Index (Al) are ordinal measures of MS severity based largely on the maximal distance subjects can walk (Dmax) and the time to walk 8 m (T8), respectively. At EDSS levels 6.0 to 7.0 and Al levels 3 to 6, scores are defined more by the use of ambulatory aids, rather than by Dmax or T8. We determined Dmax (up to 500 m), T8, the EDSS score, and the AI in 237 ambulatory MS patients. The maximal distance subjects could walk and T8 were strongly related to their ordinal counterparts (Spearman r = 0.65 and 0.91, respectively), but the continuous measures showed considerable variability within EDSS and AI levels that the ordinal scales did not reflect. Most of the variability occurred at EDSS levels 6.0 to 7.0 and AI levels 3 to 6. Because the use of an aid did not clearly predict Dmax or T8, many patients in these ranges had better ambulatory function based on the continuous measures than those with less disability according to the ordinal scales. We found that Dmax and T8 provide more precise information about ambulatory impairment in MS than do the EDSS and AI, allowing better discrimination of differences between patients and potentially greater sensitivity to detect therapeutic effects in clinical trials.
引用
收藏
页码:1419 / 1424
页数:6
相关论文
共 16 条
[1]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[2]   AN ASSESSMENT OF DISABILITY RATING-SCALES USED IN MULTIPLE-SCLEROSIS [J].
FRANCIS, DA ;
BAIN, P ;
SWAN, AV ;
HUGHES, RAC .
ARCHIVES OF NEUROLOGY, 1991, 48 (03) :299-301
[3]   INTERRATER AND INTRARATER SCORING AGREEMENT USING GRADES 1.0 TO 3.5 OF THE KURTZKE EXPANDED DISABILITY STATUS SCALE (EDSS) [J].
GOODKIN, DE ;
COOKFAIR, D ;
WENDE, K ;
BOURDETTE, D ;
PULLICINO, P ;
SCHEROKMAN, B ;
WHITHAM, R ;
JACOBS, L ;
MUNSCHAUER, F ;
EMRICH, L ;
GRANGER, C ;
HERNDON, R ;
RUDICK, R ;
FISCHER, J ;
SIMON, J ;
SALAZAR, A .
NEUROLOGY, 1992, 42 (04) :859-863
[4]   INTENSIVE IMMUNOSUPPRESSION IN PROGRESSIVE MULTIPLE-SCLEROSIS - A RANDOMIZED, 3-ARM STUDY OF HIGH-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE, PLASMA-EXCHANGE, AND ACTH [J].
HAUSER, SL ;
DAWSON, DM ;
LEHRICH, JR ;
BEAL, MF ;
KEVY, SV ;
PROPPER, RD ;
MILLS, JA ;
WEINER, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (04) :173-180
[5]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[6]   COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
JOHNSON, KP ;
BROOKS, BR ;
COHEN, JA ;
FORD, CC ;
GOLDSTEIN, J ;
LISAK, RP ;
MYERS, LW ;
PANITCH, HS ;
ROSE, JW ;
SCHIFFER, RB ;
VOLLMER, T ;
WEINER, LP ;
WOLINSKY, JS ;
BIRD, SJ ;
CONSTANTINESCU, C ;
KOLSON, DL ;
GONZALEZSCARANO, F ;
BRENNAN, D ;
PFOHL, D ;
MANDLER, RN ;
ROSENBERG, GA ;
JEFFREY, C ;
BARGER, GR ;
GANDHI, B ;
MOORE, PM ;
ROGERS, LR ;
LISAK, D ;
SMITH, L ;
ELLISON, GW ;
BAUMHEFNER, RW ;
CRAIG, SL ;
JALBUT, SS ;
KATZ, E ;
CONWAY, KL ;
BURNS, JB ;
SHIBA, C ;
GIANG, DW ;
PETRIE, MD ;
GUARNACCIA, JB ;
ANDERSON, S ;
MCKEON, A ;
MCCARTHY, M ;
THOMAS, AB ;
VRIESENDORP, FJ ;
AUSTIN, SG ;
LINDSEY, JW ;
DIMACHKIE, M ;
CERRETA, E ;
KACHUCK, N ;
MCCARTHY, KA .
NEUROLOGY, 1995, 45 (07) :1268-1276
[7]   LONGITUDINAL MRI IN MULTIPLE-SCLEROSIS - CORRELATION BETWEEN DISABILITY AND LESION BURDEN [J].
KHOURY, SJ ;
GUTTMANN, CRG ;
ORAV, EJ ;
HOHOL, MJ ;
AHN, SS ;
HSU, L ;
KIKINIS, R ;
MACKIN, GA ;
JOLESZ, FA ;
WEINER, HL .
NEUROLOGY, 1994, 44 (11) :2120-2124
[8]  
KURLAN R, 1993, HDB TOURETTES SYNDRO, P199
[9]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[10]   INTERRATER VARIABILITY WITH THE EXPANDED DISABILITY STATUS SCALE (EDSS) AND FUNCTIONAL-SYSTEMS (FS) IN A MULTIPLE-SCLEROSIS CLINICAL-TRIAL [J].
NOSEWORTHY, JH ;
VANDERVOORT, MK ;
WONG, CJ ;
EBERS, GC .
NEUROLOGY, 1990, 40 (06) :971-975